NCT00004249View on ClinicalTrials.gov

Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 1998

Primary Completion Date

November 30, 2001

Study Completion Date

November 30, 2001

Conditions
Lung Cancer
Interventions
BIOLOGICAL

QS21

BIOLOGICAL

keyhole limpet hemocyanin

DRUG

polysialic acid

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00004249 - Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy | Biotech Hunter | Biotech Hunter